H. I. Kornblum

This study compares tumor endothelial cells from low-grade and high-grade gliomas, finding they have distinct molecular profiles and functional roles in regulating tumor growth.

This study shows that a softer matrix microenvironment induces glioblastoma cells to shift toward glycolysis, increasing migration and decreasing proliferation.

This study identifies de novo pyrimidine synthesis as a therapeutic target in IDH mutant gliomas, showing that DHODH inhibitors are effective in preclinical models.

This study identifies fluoxetine as a potential therapy for glioblastoma by inhibiting SMPD1 and enhancing temozolomide efficacy, with real-world evidence suggesting improved survival.

This study uses pathway analysis to identify E2F1 as a key driver of glioblastoma proliferation and shows its inhibition sensitizes tumors to radiation.

The paper shows radiation induces vascular-like phenotypes in glioma stem cells, creating a trophic niche that promotes tumor recurrence, and identifies P300 inhibition as a potential therapeutic strategy.

This study shows that glioblastoma uses fatty acids and ketone bodies for growth, and that ketogenic diet therapy does not effectively inhibit tumor progression.

This paper develops an injectable hydrogel to deliver paclitaxel for glioblastoma treatment, achieving high local concentrations and improved survival in mice, but tumor cells can still escape the treatment area.

The paper identifies immune-suppression signatures in glioblastoma (GBM) patients, showing elevated myeloid-derived suppressor cells (MDSCs) linked to poor prognosis and reduced survival.